Original Article
Efficacy of Lower Dose Capecitabine in Patients with Metastatic Breast Cancer and Factors Influencing Therapeutic Response and Outcome
Abstract
Objective: Capecitabine exerts considerable therapeutic efficacy in metastatic breast cancer (MBC) patients previously treated with anthracyclines and taxanes.
Materials and Methods: In this study, the efficacy and safety of lower dose capecitabine (2000 mg/m2/d) in patients with anthracycline- and taxane-pretreated MBC were studied with a special emphasis on the potential predictors of time to tumor progression (TTP) and response to the capecitabine treatment.
Results: The overall response rate (ORR) was 17%. The median TTP was 5 months. Among various factors analyzed, univariate analysis showed that a performance status (PS) of 2 and the presence of visceral metastases were inversely correlated with TTP. Multivariate analysis showed that a poor PS score was associated with impaired TTP.
Conclusions: Our study indicates that lower dose capecitabine has substantial antitumor activity and a favorable safety profile in the treatment of anthracycline- and taxane-pretreated MBC. Also, only performance score was demonstrated to be a significant parameter affecting TTP.
Key Points
* The therapy of metastatic breast cancer is palliative and systemic treatment options mainly consist of chemotherapy, hormonal therapy, as well as the targeted therapies.
* Capecitabine is active against anthracycline- and taxane-pretreated metastatic breast cancer. The use of capecitabine at the FDA-approved dose (2500 mg/m2/day) leads to unacceptable toxicity in many patients. Anecdotal reports have suggested that dose reductions improve tolerability without compromising efficacy.
* Factors influencing therapeutic response to capecitabine have not been clearly demonstrated.
* Our study showed that a lower starting dose (2000 mg/m2/day) of capecitabine improves tolerability without compromising efficacy in pretreated metastatic breast cancer. However, a phase III, randomized, multicenter study to establish the safety and efficacy of different doses of capecitabine is needed.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.